Group 1 - The core viewpoint of the news is that Jindike Biotechnology Co., Ltd. has seen a stock price increase of 5.4%, reaching 16.19 yuan per share, with a total market capitalization of 1.995 billion yuan [1] - Jindike, established on December 29, 2008, focuses on the research, production, and sales of human vaccines, with 100% of its main business revenue derived from vaccine products [1] - The trading volume for Jindike was 9.7898 million yuan, with a turnover rate of 0.50% [1] Group 2 - According to data, Qianhai Kaiyuan Fund holds a significant position in Jindike, with 13,700 shares representing 1.11% of the fund's net value, making it the fifth-largest holding [2] - The Qianhai Kaiyuan Strong Consensus 100 Fund (001849) has a total asset size of 17.2629 million yuan and has achieved a year-to-date return of 11.61% [2] - The fund's performance over the past year shows a return of 15.43%, ranking 2778 out of 3868 in its category [2]
金迪克股价涨5.4%,前海开源基金旗下1只基金重仓,持有1.37万股浮盈赚取1.14万元